ATE424217T1 - Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen - Google Patents

Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen

Info

Publication number
ATE424217T1
ATE424217T1 AT98963052T AT98963052T ATE424217T1 AT E424217 T1 ATE424217 T1 AT E424217T1 AT 98963052 T AT98963052 T AT 98963052T AT 98963052 T AT98963052 T AT 98963052T AT E424217 T1 ATE424217 T1 AT E424217T1
Authority
AT
Austria
Prior art keywords
chemokines
compositions
vaccines
efficiency
increase
Prior art date
Application number
AT98963052T
Other languages
English (en)
Inventor
Robert Gallo
Anthony Devico
Alfredo Garzino-Demo
Original Assignee
Univ Maryland Biotech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland Biotech Inst filed Critical Univ Maryland Biotech Inst
Application granted granted Critical
Publication of ATE424217T1 publication Critical patent/ATE424217T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98963052T 1997-12-11 1998-12-11 Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen ATE424217T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6928197P 1997-12-11 1997-12-11

Publications (1)

Publication Number Publication Date
ATE424217T1 true ATE424217T1 (de) 2009-03-15

Family

ID=22087917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963052T ATE424217T1 (de) 1997-12-11 1998-12-11 Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen

Country Status (6)

Country Link
EP (1) EP1037918B1 (de)
AT (1) ATE424217T1 (de)
AU (1) AU1815899A (de)
CA (1) CA2314006A1 (de)
DE (1) DE69840637D1 (de)
WO (1) WO1999029728A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315653T1 (de) * 1998-04-22 2006-02-15 Chiron Corp Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US7708983B2 (en) 1998-12-11 2010-05-04 Alfredo Garzino-Demo Directional induction of immune response by co-administration of antigens with chemokines
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
AU2001253481A1 (en) * 2000-04-21 2001-11-07 Chemocentryx, Inc. Methods and compositions for eleciting an immune response
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
EP1274454B1 (de) * 2000-04-21 2005-12-28 Chemocentryx, Inc. Methoden und zusammensetzungen zur induzierung einer immunantwort
AU2002228729A1 (en) * 2001-04-12 2002-11-05 Chemocentryx Methods and compositions for inducing an immune response to an antigen
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
CN115975053B (zh) * 2022-12-07 2025-02-18 南开大学 靶向新型冠状病毒的疫苗
CN119113100B (zh) * 2024-09-26 2025-11-25 江苏立维斯德生物技术有限公司 一种重组带状疱疹疫苗组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
PL318594A1 (en) * 1995-06-07 1997-06-23 Icos Corp Chemokine and analogues thereof originating from macrophages

Also Published As

Publication number Publication date
DE69840637D1 (de) 2009-04-16
WO1999029728A1 (en) 1999-06-17
EP1037918B1 (de) 2009-03-04
CA2314006A1 (en) 1999-06-17
AU1815899A (en) 1999-06-28
EP1037918A1 (de) 2000-09-27
EP1037918A4 (de) 2004-11-03

Similar Documents

Publication Publication Date Title
DK1117672T3 (da) Antisense-modulation af survivin-ekpression
AR026994A1 (es) Nuevas construcciones de expresion en plantas.
DE60143901D1 (de) Antisense-modulation der clusterinexpression
EP1419168A4 (de) Antisense-modulation der expression von apolipoprotein b
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
EP1461352A4 (de) Antisense-modulation der expression von bindegewebewachstumsfaktor
EP1131465A4 (de) Antisense-modulierung der interleukin-15 expression
FI963070A0 (fi) Klooripyrimidiinivälituotteita
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
BG103141A (en) Composition of a malaria vaccine
EP1018976A4 (de) Behandlungskammer zur aufnahme des kopfes von versuchstieren
SE9801455D0 (sv) New receptor
DE68911132D1 (de) Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils.
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
EA199800819A1 (ru) Способ лечения биполярного расстройства
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
DE59809344D1 (de) Disubstituierte biphenyloxazoline
DE60207574D1 (de) Verwendung von oxytocin zur stimulierung des pflanzenwachstums
DE50109166D1 (de) Verfahren zur verbesserung der transfektionseffizienz
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties